Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Depreciation and Depletion (2016 - 2017)

CytomX Therapeutics' Depreciation and Depletion history spans 2 years, with the latest figure at $400000.0 for Q4 2017.

  • For Q4 2017, Depreciation and Depletion fell 20.0% year-over-year to $400000.0; the TTM value through Dec 2017 reached $1.7 million, changed N/A, while the annual FY2025 figure was $1.2 million, 25.0% down from the prior year.
  • Depreciation and Depletion reached $400000.0 in Q4 2017 per CTMX's latest filing, up from $368000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $500000.0 in Q4 2016 to a low of $368000.0 in Q3 2017.